Claims
- 1. A method of treating celiac disease comprising administration of a composition containing an alkanoyl L-carnitine wherein the alkanoyl group is straight or branched and has 2-6 carbon atoms or a pharmacologically acceptable salt thereof.
- 2. A method of claim 1, wherein the alkanoyl L-carnitine is selected from the group consisting of acetyl, propionyl, butyryl, isobutyryl, valeryl and isovaleryl L-carnitine.
- 3. A method of claim 1, wherein administration is selected from the group consisting of oral, parenteral and rectal route.
- 4. A method of claim 3, wherein said route is oral.
- 5. A method of claim 1, wherein said composition further comprises at least one active agent used for the treatment of celiac disease.
- 6. A method of claim 5, wherein said active agent is a corticosteroid having an anti-inflammatory action.
- 7. A method of claim 6, wherein said corticosteroid is selected from the group consisting of hydrocortisone, betamethasone, prednisone, prednisolone and fluticasone.
- 8. A method of claim 5, wherein said active agent is a short chain fatty acid.
- 9. A method of claim 5, wherein said active agent is an amino acid.
- 10. A method of claim 9, wherein said amino acid is glutamine.
- 11. A method of claim 3, wherein said route is rectal.
- 12. A method of claim 11, wherein in said rectal route, said composition further comprises at least one active agent used for the treatment of celiac disease.
- 13. A method of claim 12, wherein said active agent is a corticosteroid having an anti-inflammatory action.
- 14. A method of claim 13, wherein said corticosteroid is selected from the group consisting of hydrocortisone, betamethasone, prednisone, prednisolone and fluticasone.
- 15. A method of claim 12, wherein in said rectal route, said active agent is a short chain fatty acid.
- 16. A method of claim 12, wherein in said rectal route, said active agent is an amino acid.
- 17. A method of claim 16, wherein in said rectal route, said said amino acid is glutamine.
- 18. A method of claim 11, wherein in said rectal route, said composition is in the form of foam or enema, said foam or enema further comprising a compound selected from the group consisting of an anti-diarrhoea agent, antibiotic, anaesthetic, stool softener and a lubricant.
- 19. A method of claim 12, wherein in said rectal route, said composition is in the form of foam or enema, said foam or enema further comprising a compound selected from the group consisting of an anti-diarrhoea agent, antibiotic, anaesthetic, stool softener and a lubricant.
- 20. A method of claim 1 wherein said pharmacologically acceptable salt of alkanoyl L-carnitine is selected from chloride, bromide, orotate, acid aspartate, acid citrate, acid phosphate, fumarate and acid fumarate, lactate, maleate and acid maleate, acid oxalate, acid sulphate, glucose phosphate, tartrate and acid tartrate.
Priority Claims (1)
Number |
Date |
Country |
Kind |
RM96A0396 |
Jun 1996 |
IT |
|
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of earlier application Ser. No. 09/441,328 filed Nov. 16, 1999, now U.S. Pat. No. 6,143,785, which is a division of Ser. No. 08/868,627 filed Jun. 4, 1997, now U.S. Pat. No. 6,013,607.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4958418 |
Dufour |
Sep 1990 |
A |
Foreign Referenced Citations (3)
Number |
Date |
Country |
1-156927 |
Jun 1989 |
JP |
WO 97272177 |
Jul 1997 |
WO |
WO 9956698 |
Nov 1999 |
WO |
Non-Patent Literature Citations (3)
Entry |
Lerner et al, Gut (1993) 34,933-935 Serum carnitine concentrations in coeliac disease. |
Ceccarelli et al Minerva Pediatrica (1992) vol. 44, No. 9, 401-405 Concentrazioni plasmatiche di L-carnitine in bambini celiaci. |
English translation Italian patent appln. RM 96A 00396 filed Jun. 6, 1996. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09/441328 |
Nov 1999 |
US |
Child |
09/626151 |
|
US |